What is inclusion body myositis?

Inclusion Body Myositis (IBM) is a rare, progressive muscle disease characterized by chronic muscle inflammation and weakness. It is the most common acquired muscle disease in adults over 50, affecting approximately 20,000 people in the United States.

Sporadic IBM (sIBM), the most common form, is NOT inherited — it occurs randomly. However, about 67% of patients carry a specific HLA gene combination that makes them genetically susceptible. Hereditary Inclusion Body Myopathies (hIBM) are a separate group of genetic muscle diseases.

Is there a cure for IBM?

As of 2026, there are no FDA-approved treatments specifically for IBM. The disease is notoriously resistant to corticosteroids and immunosuppressive drugs. Physical therapy and adaptive strategies are the mainstay of management. Active research is underway with promising clinical trials.

Does IBM qualify for disability benefits?

Yes. IBM is listed under Section 11.15 (Disorders of the Peripheral Nervous System) in the SSA Blue Book for Social Security Disability Insurance (SSDI). The IBM Functional Rating Scale can support your application.

What exercises are safe with IBM?

Walking, aquatic therapy, light resistance training, balance training, and hand/finger exercises are all recommended for IBM patients. Start slowly, build over 6-12 weeks, and consult with a physical therapist who understands myositis.

Why is IBM often misdiagnosed?

IBM is frequently misdiagnosed as polymyositis, normal aging, fibromyalgia, ALS, or sarcopenia. The average diagnostic delay is 5-10 years from symptom onset because IBM shares symptoms with more common conditions.

What is the treatment for inclusion body myositis?

There is no FDA-approved treatment that stops or reverses IBM. Current management focuses on maintaining function through physical therapy and exercise, managing symptoms like dysphagia (difficulty swallowing), and using adaptive equipment. Some patients receive IVIg (intravenous immunoglobulin) which may provide modest, temporary benefit in a subset of patients.

Does IBM respond to steroids?

No. Unlike polymyositis and dermatomyositis, IBM is notoriously resistant to corticosteroids and immunosuppressive drugs. This is because IBM has a dual pathology — autoimmune inflammation combined with degenerative protein aggregation — and immunotherapy only addresses the inflammatory component.

Are there clinical trials for IBM?

Yes. Active clinical trials are investigating rapamycin (sirolimus), BCG vaccine, anti-amyloid therapies, and CAR T-cell approaches. Visit ClinicalTrials.gov and search for "inclusion body myositis" to find current recruiting studies.

What is IVIg and does it help IBM?

IVIg (intravenous immunoglobulin) is a treatment derived from donated blood plasma that modulates the immune system. Some studies suggest modest benefit in a small number of IBM patients, particularly for improving strength temporarily. However, benefits are generally short-lived and the treatment is expensive.

IBM Treatment Options 2026 — What Works, What Doesn't

The Current Reality

As of 2026, there is no FDA-approved treatment that stops, slows, or reverses IBM. This is the single most important thing to understand about this disease. Unlike polymyositis and dermatomyositis, IBM does not respond to corticosteroids or immunosuppressive drugs. Management focuses on maintaining function, managing symptoms, and adapting to changing abilities.

Why IBM resists standard treatmentIBM has a dual pathology: autoimmune inflammation AND degenerative protein aggregation (amyloid-beta, TDP-43). Standard immunotherapy only addresses the inflammation. The degenerative component continues regardless of immune suppression.

What Currently Works

Exercise and Physical Therapy

Exercise is the only proven intervention for IBM. Research confirms it is safe and can improve quality of life. Walking, aquatic therapy, light resistance training, and balance training are all recommended. The goal is to maintain what you have — muscles begin losing strength within 24-48 hours of inactivity. Start with TMA's IBM Home Exercise Program and work with a physical therapist who understands myositis.

IVIg (Intravenous Immunoglobulin)

IVIg is derived from donated blood plasma and modulates the immune system. Some studies suggest modest, temporary benefit in a subset of IBM patients. Benefits are generally short-lived and the treatment is expensive (typically $5,000-10,000 per infusion). Not all patients respond, and insurance coverage varies.

Dysphagia Management

Difficulty swallowing affects 40-85% of IBM patients and is a major cause of morbidity. A speech-language pathologist can evaluate swallowing function and recommend dietary modifications, swallowing exercises, or in severe cases, a feeding tube. Aspiration pneumonia is the leading cause of death in myositis patients.

Adaptive Equipment and Home Modifications

As weakness progresses, adaptive equipment maintains independence. Patient lifts, bidets, wheelchair modifications, and home modifications (grab bars, ramp access, stairlifts) allow continued living at home. Early planning prevents crisis situations.

Fall Prevention

IBM patients have 2.5x higher fall risk than other inflammatory myopathy patients. Falls can cause hip fractures, skull fractures, and other serious injuries. Grab bars, non-slip flooring, balance training, and bone density monitoring (with calcium and vitamin D supplementation) are essential.

What Does NOT Work

These treatments have been studied and shown to be ineffective for IBM:

Corticosteroids (prednisone): Effective for polymyositis and dermatomyositis but ineffective for IBM. Long-term use causes serious side effects including osteoporosis, diabetes, and weight gain.
Methotrexate: An immunosuppressive drug commonly used for other autoimmune conditions. Studies have not shown benefit for IBM.
Azathioprine: Another immunosuppressive drug. No demonstrated benefit for IBM.
Mycophenolate mofetil: Used for other inflammatory myopathies. Not effective for IBM.

If you have been prescribed any of these medications for IBM, discuss with your doctor whether they are providing any benefit. Continuing ineffective treatment exposes you to side effects without addressing the disease.

Active Clinical Trials and Emerging Treatments

The research pipeline for IBM is more active than it has ever been. Several approaches are being investigated:

Rapamycin (Sirolimus)

An mTOR inhibitor originally developed as an immunosuppressant, rapamycin is being studied for its potential to reduce protein aggregation and improve autophagy (the cell's cleanup system). Early results are mixed — some studies show potential benefit while others have been disappointing. Multiple clinical trials are ongoing.

BCG Vaccine

The BCG vaccine (used for tuberculosis) is being investigated for IBM based on its immune-modulating properties. A clinical trial at Yale is examining whether BCG can improve muscle function in IBM patients.

CAR T-Cell Therapy

Data from the EULAR 2026 Annual Meeting showed early results from the RESET-Myositis trial testing rese-cel (formerly CABA-201) in inflammatory myopathies. Results were mixed — 80% of dermatomyositis patients improved, but myositis patients had a 37.5% relapse rate. IBM-specific trials are needed.

Anti-Amyloid Therapies

Since IBM involves amyloid-beta protein aggregation (similar to Alzheimer's disease), some researchers are exploring whether anti-amyloid drugs used for Alzheimer's could help IBM. This is still in early investigation stages.

Finding Clinical TrialsVisit ClinicalTrials.gov and search for "inclusion body myositis" to find current recruiting studies. The Myositis Association (myositis.org) also maintains a list of active trials and can help connect you with research centers.

Specialist Care

IBM is rare — most general neurologists and rheumatologists will see only a handful of cases in their career. Seeking care from a myositis specialist can make a significant difference in management and access to clinical trials.

Specialist Centers

Johns Hopkins Myositis Center — hopkinsmyositis.org — One of the leading myositis research and treatment centers
Yale IBM Registry — ysph.yale.edu/ibmregistry — Contribute to research and access specialist care
Cleveland Clinic — my.clevelandclinic.org — Neurological Institute with myositis expertise
Mayo Clinic — mayoclinic.org — Neuromuscular disease center
The Myositis Association — myositis.org — Find a Doctor directory for myositis-experienced specialists

What You Can Do Today

Exercise: Start or continue a regular exercise program. Walking is always safe at your own pace.
Get a swallowing evaluation: Don't wait for symptoms. A speech-language pathologist can catch problems early.
Plan for equipment: Don't wait for a crisis. Research patient lifts, bidets, and home modifications before you need them urgently.
Find a specialist: Seek care from a neurologist or rheumatologist experienced with myositis.
Check clinical trials: Visit ClinicalTrials.gov and myositis.org for current recruiting studies.
Apply for disability early: If IBM is affecting your ability to work, apply for SSDI. The IBM Functional Rating Scale supports your application.

Inclusion Body Myositis Treatment